Unlock instant, AI-driven research and patent intelligence for your innovation.

Alpha-mangostin derivatives and their applications

A technology of drugs and compounds, applied in the field of medicine

Active Publication Date: 2022-07-22
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no approved drugs for the treatment of VaD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alpha-mangostin derivatives and their applications
  • Alpha-mangostin derivatives and their applications
  • Alpha-mangostin derivatives and their applications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1. Preparation of compounds 2b-2c, 3a-3g.

[0062] Synthesis of Intermediate 1: α-Mangostin (5.0 g, 12.18 mmol) was dissolved in dry benzene (80 mL) followed by addition of dichlorodicyanobenzoquinone (DDQ) (3.0, 13.39 mmol). The reaction solution was heated to 80°C and refluxed for 3h. After the reaction was completed, filter while hot and evaporate the solvent in the filtrate to dryness. The obtained crude product was subjected to silica gel column chromatography (V 乙酸乙酯 : V 石油醚 =3:20) and purified to obtain yellow solid 1 (4.1 g, 10.04 mmol, yield 82%).

[0063] Compound: 5,9-Dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-2H,-6H-pyrano[ 3,2-B]xanthene-6-one 5,9-dihydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-2H,6H-pyrano[ 3,2-B]xanthen-6-one(1). Yield: 82%. 1 H NMR (400MHz, CDCl 3 )δ13.69(s, 1H), 6.82(s, 1H), 6.72(d, J=10.2Hz, 1H), 6.35(s, 1H), 6.24(s, 1H), 5.56(d, J=10.0 Hz,1H),5.31-5.21(m,1H),4.08(d,J=6.3Hz,2H),3.80(s,3H),1.83...

Embodiment 2

[0085] Example 2. Preparation of compounds 4a-4g.

[0086] Synthesis of compound 4a: Hydroxylamine hydrochloride (31 mg, 0.44 mmol) and sodium hydroxide (44 mg, 1.10 mmol) were dissolved in dry acetone (3 mL). After the reaction solution was stirred at room temperature for 10 minutes, 3a (110 mg, 0.22 mmol) was added and heated to 50° C. and refluxed for 6 h. After the reaction was completed, 10 ml of 5% dilute sulfuric acid was added and extracted three times with an equal volume of ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was evaporated to dryness, and the obtained crude product was subjected to silica gel column chromatography (V 甲醇 : V 二氯甲烷 =1:99) was purified to obtain yellow solid 4a (60.5 mg, 0.13 mmol, yield 59%).

[0087] Synthesis of compound 4b: Hydroxylamine hydrochloride (32 mg, 0.46 mmol) and sodium hydroxide (46 mg, 1.15 mmol) were dissolved in dry acetone (5 mL). After the reaction solution ...

Embodiment 3

[0101] Example 3. Preparation of Compound 5.

[0102] Synthesis of compound 5: 2b (56.4 mg, 0.10 mmol) and potassium carbonate (166 mg, 1.20 mmol) were dissolved in dry acetone (5 mL), followed by the addition of pyrrolidine (0.1 ml, 1.21 mmol). The reaction solution was heated to 50°C and refluxed overnight. After the reaction, 10 ml of water was added and extracted three times with an equal volume of ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. The organic phase was evaporated to dryness, and the obtained crude product was subjected to silica gel column chromatography (V 甲醇 : V 二氯甲烷 =3:97) was purified to obtain yellow solid 5 (40 mg, 0.07 mmol, 71% yield).

[0103] Compound: 5-Hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut-2-en-1-yl)-9-((6-(pyrrolidine-1- yl)hexyl)oxy)-2H,-6H-pyrano[3,2-b]xanthene-6-one (5-hydroxy-8-methoxy-2,2-dimethyl-7-(3-methylbut -2-en-1-yl)-9-((6-(pyrrolidin-1-yl)hexyl)oxy)-2H,6H-pyrano[3,2-b]xanthen-6-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses α-mangostin derivatives and applications thereof, wherein the derivatives are compounds with general formula (I), their deuterated products, pharmaceutically acceptable salts or solvates: wherein, n=1~18; R 1 Selected from carboxyl and pyrrolidine groups. Use of the compound of formula I of the present invention in the preparation of a medicament for treating diseases mediated by phosphodiesterase 4, improving cognitive function or treating vascular dementia. The present invention confirms that these compounds can significantly inhibit PDE4 with high selectivity, and in vivo experiments also prove that these compounds can improve cognitive function and treat vascular dementia.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to α-mangostin derivatives and applications thereof. Background technique [0002] Phosphodiesterases (PDEs), an 11-member enzyme superfamily responsible for degrading the second messengers cGMP and cAMP, have received extensive attention as drug targets for central nervous system (CNS) diseases. PDE4 (specifically hydrolyzes cAMP) is distributed throughout the central nervous system and is thought to play an important role in learning and memory processes by regulating the cAMP / PKA / CREB pathway. There are more than 20 different variants of PDE4, encoded by four isoforms (PDE4A, PDE4B, PDE4C, and PDE4D). These four PDE isoforms have distinct targeting and regulatory properties in the central nervous system, which is also partly reflected by their distinct distribution patterns in brain regions. PDE4 inhibitors (eg, rolipram, roflumilast, apremilast, and alpha-mangostin) have shown ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/04A61K31/352A61K31/4025A61P29/00A61P17/06A61P11/00A61P1/00A61P11/06A61P25/28A61P21/00A61P25/18A61P25/16A61P25/14A61P25/24A61P9/10
CPCC07D493/04A61P29/00A61P17/06A61P11/00A61P1/00A61P11/06A61P25/28A61P21/00A61P25/18A61P25/16A61P25/14A61P25/24A61P9/10
Inventor 何细新罗海彬梁津豪黄仪有于思
Owner GUANGZHOU UNIVERSITY OF CHINESE MEDICINE